🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Monoclonal antibodies have potential to treat infectious diseases in LMICs, but high costs and slow production hinder access. Our own Chun Chen, highlights three strategies to improve efficiency: 1️⃣ Scale up 2️⃣ Scale out 3️⃣ Scale by time Read more: bioprocessonline.com/doc/strategies…

TB is the leading infectious killer but scientific breakthroughs could change that. On #WorldTBDay, I spoke with Gates Medical Research Institute CEO Patrice Matchaba about what’s ahead - from the M72 vaccine candidate to new diagnostics & drugs. Continued global collaboration is essential to #EndTB

After decades of research and implementation, the World Health Organization (WHO) has officially declared Georgia malaria-free. Effective health care policies, mosquito control and treatments have led the WHO European Region to eliminate malaria for future generations. who.int/news/item/23-0…

The rollout of the R21/Matrix-M vaccine in Nigeria can help protect children against malaria and offers hope to families throughout the country and region. With government and community support, Nigeria is making progress against malaria. gavi.org/vaccineswork/n…

The FDA granted Breakthrough Device Designation to Intelligenome’s CRISPR-Tuberculosis (TB) Blood Test. This test uses CRISPR tech to detect TB in blood samples, which could help with public screening and early diagnosis of TB. biospace.com/press-releases…

A study found resistance to the malaria drug artemisinin in Uganda. 11 out of 100 kids had repeat infections within 28 days, showing partial resistance. We must prioritize innovative solutions to tackle this rising threat. nature.com/articles/d4414…

We're glad to announce the Phase 3 trial of the M72/AS01E TB vaccine is fully enrolled. Thanks to all our partners and trial participants, we’re closer to understanding the safety and efficacy of the candidate. A novel TB vaccine is critical to the vision of a world without TB.

To tackle public health threats, local scientists need access to the right resources. ClinOps provides African scientists with clinical trial training to enhance research and innovation. By investing in programs like this, we can advance global health. bmcmededuc.biomedcentral.com/articles/10.11…

With full enrollment of the Phase 3 clinical trial of the M72/AS01E TB vaccine candidate ahead of schedule, we're one step closer to what could be, if proven well tolerated and efficacious, the first new TB vaccine in over a century.

The Phase 3 trial of the M72/AS01E tuberculosis (TB) vaccine candidate has reached full enrollment, with approx. 20,000 participants across 5 countries, a major step in this important trial. More in STAT: statnews.com/2025/04/28/maj…

Tuberculosis (TB) remains a global health challenge. Our own Alemnew Dagnew led a study using Group-Based Trajectory Modeling to track TB notification patterns over time, identifying geographic clusters to strengthen intervention strategies. Read more: bmcpublichealth.biomedcentral.com/articles/10.11…

Treatment of TB disease is complicated by the rise of antimicrobial resistance (AMR). Reads how genomic data can predict AMR, helping clinicians tailor and improve TB treatment: nature.com/articles/s4159…

TB cases among children under 15 in the World Health Organization (WHO) European region rose to 7,500– 650 more than in 2022. Increased travel & better diagnostics play a role, but more substantial global TB funding is critical to prevent further setbacks. reuters.com/business/healt…

MDR-TB threatens global TB prevention, with cases highest in 15- to 19-year-olds and deaths greatest in children ages <5. Read more to better understand global trends in MDR-TB: nature.com/articles/s4139…

New genetic studies suggest that distinct strains of malaria exist in different areas of Africa, making some intervention tactics less effective. Major challenges remain in recruiting enough scientists with the expertise to help track these strains. gavi.org/vaccineswork/q…

A recent study presented at ESCMID revealed that more than 3 million children, particularly in Southeast Asia and Africa, died from antimicrobial resistant (AMR) infections in 2022. Read more about the threat here: gavi.org/vaccineswork/m…